| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 85 | 13.7x | 17.3x | Top tier | |
Growth | 48 | 2.3% | 7.1% | Around median | |
Quality | 57 | 8.8% | 4.5% | Around median | |
Safety | 51 | 3.3x | 2.6x | Around median | |
Capital Return | 78 | 1.89% | 0.06% | Top tier | |
Momentum | 29 | -16.1% | -1.6% | Bottom tier | |
Sentiment | 91 | 5 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
44% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
H.B. Fuller develops and sells adhesives, coatings, and protective barriers for multiple industrial and consumer markets, generating revenue through three business units: HHC, EA, and BAS. Its applications include packaging, hygiene, labels, aerospace, automotive, electronics, roofing, and insulating glass, and it focuses on developing higher-value materials that help customers improve performance and reduce the amount of material used. Management says the global adhesives market is approximately $80 billion, while H.B. Fuller’s share is less than 5%, leaving room to gain share through innovation and reliable supply.
In fiscal Q3 2026, net revenue was approximately $938 million, up 5.2% year over year, while organic revenue increased 4.4% due to a 7.4% price increase despite a 3% decline in volume. Adjusted earnings before interest, taxes, depreciation, and amortization were $187 million, up 9%, and the margin expanded by 80 basis points to 19.9%, while adjusted gross profit margin increased by 120 basis points to 33.5%. Adjusted earnings per share were $1.52, up 21% from fiscal Q3 2025, while fiscal year-to-date operating cash flow increased 17% to $183 million.
At the business-unit level, HHC organic revenue grew 6%, and its adjusted earnings before interest, taxes, depreciation, and amortization margin reached 17.6%, supported by hygiene, beverage labels, tapes, and labels despite weakness in packaging. EA grew organically by approximately 5% excluding solar, with a margin of 23.8%, while electronics weakness resulting from chip shortages reduced reported growth including solar to 1%. BAS organic revenue grew 5%, and its earnings before interest, taxes, depreciation, and amortization increased 8%, benefiting from roofing and insulating glass despite weakness in wood and a subdued construction environment.
The average analyst price target is $66.80, approximately 2.7% below the 52-week range high of $68.63, with a wide target range of $58 to $73 and a consensus rating of “Buy.” The 52-week range of $46.70 to $68.63 indicates a volatile revaluation, as the market balances earnings and margin growth on one hand against lower volumes, raw-material disruption, and Advanced Medical Solutions financing risks on the other.
Figures in the text are as of 2026-09-25; the live price is shown at the top of the page.
Net revenue was approximately $938 million, up 5.2% year over year, and organic revenue grew 4.4%. Growth came from a 7.4% price increase, while volumes declined 3%. Adjusted earnings before interest, taxes, depreciation, and amortization increased 9% to $187 million, while adjusted earnings per share rose 21% to $1.52.
The program targets $75 million in annual conversion-cost savings by the end of fiscal 2030. The company expects to achieve approximately $25 million in savings by the end of fiscal 2026, then add $20 million to $25 million in fiscal 2027. It also plans to reduce its manufacturing network from 82 facilities at the end of fiscal 2024 to approximately 62 at the end of fiscal 2026, ultimately reaching a target of 55 facilities.
The company expects mid-single-digit growth in net revenue and low-single-digit organic growth compared with fiscal 2025. Expected adjusted earnings before interest, taxes, depreciation, and amortization range from $655 million to $670 million, while adjusted earnings per share are expected to range from $4.70 to $4.85. It also expects operating cash flow of between $300 million and $325 million, excluding items related to Advanced Medical Solutions.
Automated analysis for informational purposes only — not investment advice.
H.B. Fuller believes the transaction strengthens its portfolio and increases its presence in the faster-growing surgical tissue-closure market, which is less correlated with industrial and construction cycles. Advanced Medical Solutions recorded 4% revenue growth and 8% growth in adjusted earnings before interest, taxes, depreciation, and amortization during the first half of fiscal 2026. H.B. Fuller expects average annual growth of approximately 8% for the target business and intends to complete the transaction before the end of fiscal 2026 after obtaining the required regulatory approvals.
Management identified China and construction as the two main risk areas in fiscal 2027, amid weakness in Chinese consumer and export markets and continued softness in residential construction. In EA, chip shortages pressured phone production in Asia-Pacific, while electric-vehicle shipments in China also declined during fiscal Q3 2026. In HHC, lower packaged-food consumption and weak household formation had an impact, while management said volumes in this unit declined by approximately 9% over two years.
Fiscal 2026 year-to-date operating cash flow was approximately $183 million, up 17% year over year, and net debt to adjusted earnings before interest, taxes, depreciation, and amortization declined to slightly below 3 times. The company expects that reducing inventory by five days will release approximately $35 million in working capital and that reducing the plant network will lower maintenance capital expenditure by approximately $15 million. After completing Advanced Medical Solutions, management aims to return leverage to a range of 2.5–3 times within two years, but achieving this depends on cash generation, execution of Quantum Leap, and debt reduction.